Key Points - FDA grants priority review to BridgeBio's drug filing for infigratinib - BBIO potentially set to become the first approved oral therapy for achondroplasia - Infigratinib aimed at treating dwarfism caused by achondroplasia - BridgeBio expects FDA decision on approval by end of the year - Company seeks to provide much-needed treatment option...
Key Points - Shell (SHEL) is well positioned for market outperformance, showing above-average growth in financials...
Key Points - Rosen Law Firm urges HDFC Bank Limited investors with losses over $100K to...
Every position is an argument with someone on the other side. Here is what the numbers...
Most sessions tell you nothing. These 6 moved trivago N.V. (TRVG) enough to be worth explaining...
from Morgan Stanley issued a price target of $39.00 for BVN on 2026-10-07 14:51:28.The adjusted price target was set to $39.00.At the time of the announcement, BVN was trading at...
from Morgan Stanley issued a price target of $15.50 for VALE on 2026-10-07 14:49:35.The adjusted price target was set to $15.50.At the time of the announcement, VALE was trading at...
Srini Pajjuri from RBC Capital issued a price target of $2,100.00 for ASML on 2026-10-07 13:22:00.The adjusted price target was set to $2,100.00.At the time of the announcement, ASML was...
Michael Schmidt from Guggenheim issued a price target of $58.00 for GMAB on 2026-10-07 10:44:41.The adjusted price target was set to $58.00.At the time of the announcement, GMAB was trading...
from Goldman Sachs issued a price target of $17.70 for EC on 2026-10-07 09:59:19.The adjusted price target was set to $17.70.At the time of the announcement, EC was trading at...
In a landscape marked by financial fluctuations, the company reported a rise in other income but faced significant operating expenses, leading to a net loss. Management is focused on building...
In a landscape of rising revenues and increasing operational costs, the company navigates challenges with a focus on innovation and sustainability. Despite a dip in net income and profit declines...
In a year marked by resilience, the company celebrated record revenues of $25 billion, driven by strong ticket sales and operational efficiency. With a focus on North America, it reduced...
